People who have chronic hepatitis B and active liver damage may benefit from telbivudine. This prescription medicine works by disrupting the multiplication process of the hepatitis B virus. Although it is not a cure, telbivudine can help slow down the spread of the virus and reduce damage to the liver. Side effects may include coughing, headaches, and fatigue.
What Is Telbivudine?
Telbivudine (Tyzeka®) is a prescription medication approved to treat chronic hepatitis B infection in people age 16 and older with signs of liver damage. It is not a cure for hepatitis B, but it may reduce the amount of hepatitis B virus (HBV) in the body. Telbivudine belongs to a group of medications known as nucleoside reverse transcriptase inhibitors (NRTIs), which are sometimes simply called nucleoside analogues.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Tyzeka [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;2011 December.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed February 17, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click